Maguire MG, Liu D, Glassman AR, et al. - In view of the fact that preservation of peripheral visual field (VF) is considered a benefit for anti-vascular endothelial growth factor agents vs panretinal photocoagulation (PRP) for the treatment of proliferative diabetic retinopathy, researchers conducted this post hoc analysis of a randomized clinical trial to further assess changes in VF over a 5-year period among eyes registered in the Protocol S clinical trial, carried out by the DRCR Retina Network. Of 394 eyes registered in Protocol S, 234 were targeted for this ancillary study. In the PRP group, eyes had substantial loss of VF at 1 year and additional VF loss over time. With the absence of laser treatments, eyes in the ranibizumab group lost sensitivity to VF after 2 years. Although laser treatments reflect some of the loss of VF over time, these data suggest other processes may be associated with the degradation of VF. There was no correlation between change in point score and the number of ranibizumab injections during the previous year. Limitations of available data, however, hinder more precise conclusions.